Improving population health in US cities.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 3618470)

Published in JAMA on February 06, 2013

Authors

Nicholas W Stine1, Dave A Chokshi, Marc N Gourevitch

Author Affiliations

1: Office of Healthcare Improvement, New York City Health and Hospitals Corporation, 346 Broadway, New York, NY 10013, USA. nicholas.stine@nychhc.org

Articles by these authors

Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med (2002) 5.30

Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med (2004) 4.38

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15

Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med (2004) 2.37

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97

Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr (2007) 1.82

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80

Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73

Medical homes: challenges in translating theory into practice. Med Care (2009) 1.69

Home buprenorphine/naloxone induction in primary care. J Gen Intern Med (2008) 1.67

Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol (2005) 1.58

Medicaid patients at high risk for frequent hospital admission: real-time identification and remediable risks. J Urban Health (2008) 1.52

Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr (2007) 1.48

Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis (2005) 1.41

Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40

Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24

The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat (2005) 1.22

Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21

Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clin Infect Dis (2002) 1.14

Behavioral economics and physician compensation--promise and challenges. N Engl J Med (2015) 1.13

Opportunity in austerity--a common agenda for medicine and public health. N Engl J Med (2012) 1.10

Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors. J Acquir Immune Defic Syndr (2007) 1.10

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09

Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict (2002) 1.06

Effects of methadone on QT-interval dispersion. Pharmacotherapy (2005) 1.04

Universities should foster neglected-disease work. Nature (2005) 1.04

Analysis of a population-based Pneumocystis carinii pneumonia index as an outcome measure of access and quality of care for the treatment of HIV disease. Am J Public Health (2002) 1.04

Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey. Harm Reduct J (2006) 1.04

Unprotected sex among HIV-positive injection drug-using women and their serodiscordant male partners: role of personal and partnership influences. J Acquir Immune Defic Syndr (2006) 1.04

Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat (2010) 1.03

"Lost to follow-up": the public health goals of accountable care. Arch Intern Med (2012) 1.03

Should health care systems become insurers? JAMA (2013) 1.02

Validation of the Spanish translation of the Patient Assessment of Chronic Illness Care (PACIC) survey. Prev Chronic Dis (2008) 1.01

Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis (2006) 1.00

The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med (2003) 0.99

Connecting the dots: interprofessional health education and delivery system redesign at the Veterans Health Administration. Acad Med (2014) 0.99

Estimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health (2012) 0.96

First do no harm ... Reduction? Ann Intern Med (2009) 0.96

Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat (2007) 0.95

Factors associated with frequent utilization of crisis substance use detoxification services. J Addict Dis (2011) 0.95

Undergraduate medical education in substance abuse: a review of the quality of the literature. Acad Med (2011) 0.93

Syndemic vulnerability, sexual and injection risk behaviors, and HIV continuum of care outcomes in HIV-positive injection drug users. AIDS Behav (2015) 0.93

Community health workers--a local solution to a global problem. N Engl J Med (2013) 0.92

Buprenorphine-naloxone maintenance following release from jail. Subst Abus (2012) 0.92

Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. J Subst Abuse Treat (2012) 0.91

A 5-year evaluation of a methadone medical maintenance program. J Subst Abuse Treat (2006) 0.90

Convenient Ambulatory Care--Promise, Pitfalls, and Policy. N Engl J Med (2015) 0.90

Update in addiction medicine for the primary care clinician. J Gen Intern Med (2008) 0.89

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89

Safe syringe disposal is related to safe syringe access among HIV-positive injection drug users. AIDS Behav (2006) 0.87

Improving access to sterile syringes and safe syringe disposal for injection drug users in methadone maintenance treatment. J Subst Abuse Treat (2006) 0.86

Engaging health professional students in substance abuse research: development and early evaluation of the SARET program. J Addict Med (2012) 0.86

Monitoring the pulse of hospital activity: electronic health record utilization as a measure of care intensity. J Hosp Med (2013) 0.86

New measures to establish the evidence base for medical education: identifying educationally sensitive patient outcomes. Acad Med (2010) 0.85

Teaching physicians to address unhealthy alcohol use: a randomized controlled trial assessing the effect of a Web-based module on medical student performance. J Subst Abuse Treat (2010) 0.85

Substance use treatment barriers for patients with frequent hospital admissions. J Subst Abuse Treat (2009) 0.84

Medications that prolong the QT interval. JAMA (2003) 0.83

Substance use prevalence and screening instrument comparisons in urban primary care. Subst Abus (2011) 0.82

Community health workers: an opportunity for reverse innovation - Authors' reply. Lancet (2013) 0.82

Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr (2011) 0.81

Closing the access gap for health innovations: an open licensing proposal for universities. Global Health (2007) 0.81

Update in addiction medicine for the generalist. J Gen Intern Med (2007) 0.81

How patients understand the term "nonmedical use" of prescription drugs: insights from cognitive interviews. Subst Abus (2014) 0.80

Economic evaluation of an HIV prevention intervention for seropositive injection drug users. J Public Health Manag Pract (2005) 0.80

Agreement between Mantoux skin testing and QuantiFERON-TB assay using dual mycobacterial antigens in current and former injection drug users. Med Sci Monit (2006) 0.80

The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict (2013) 0.80

Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther (2007) 0.79

Working with patients with alcohol problems: a controlled trial of the impact of a rich media web module on medical student performance. J Gen Intern Med (2008) 0.79

Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. J Subst Abuse Treat (2007) 0.78

Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis (2003) 0.78

Technology in medical education—Osler meets Watson. J Gen Intern Med (2014) 0.78

Longitudinal correlates of health care-seeking behaviors among HIV-seropositive injection drug users: how can we intervene to improve health care utilization? J Acquir Immune Defic Syndr (2007) 0.77

Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users. J Gen Intern Med (2004) 0.76

False reduction in serum methadone concentrations by BD Vacutainer serum separator tubes (SSTTM). Clin Chem (2006) 0.76

Housing insecurity and lack of public assistance are risk factors for tuberculin skin test conversion among persons who use illicit drugs in New York City. J Addict Med (2009) 0.75

Needs-based research and development. Health Aff (Millwood) (2008) 0.75

Orienting health care reform around universal access. Arch Intern Med (2009) 0.75

Two-step tuberculin skin testing in drug users. J Addict Dis (2007) 0.75

Changes in cardiovascular care provision after the Affordable Care Act. Am J Manag Care (2017) 0.75

Addiction Research Training Programs: Four Case Studies and Recommendations for Evaluation. J Addict Med (2017) 0.75